The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

被引:0
作者
A R Gottschalk
M Roach
机构
[1] University of California,Department of Radiation Oncology and the Comprehensive Cancer Center
[2] San Francisco,undefined
[3] 1600 Divisadero St.,undefined
[4] H-1031,undefined
来源
British Journal of Cancer | 2004年 / 90卷
关键词
prostate cancer; hormonal therapy; radiation; whole-pelvic radiation; randomised trials;
D O I
暂无
中图分类号
学科分类号
摘要
In 1901, Wilhelm Conrad Röntgen won the Nobel prize in Physics for his discovery of the Röntgen rays or, as he himself called them, X-rays. In 1966, Dr Charles Brenton Higgins won the Nobel Prize in Medicine for his breakthroughs concerning hormonal treatment of prostatic cancer. After 31 years, in 1997, the first prospective randomised trials of the combination of hormonal therapy and radiation therapy were published, showing increased survival when compared to radiation therapy alone for patients with prostate cancer. Since 1997, many investigators have published trials combining hormonal and radiation therapy for prostate cancer. This minireview will address the largest and most influential of these trials, and attempt to guide physicians in selecting the appropriate patients for this combined approach.
引用
收藏
页码:950 / 954
页数:4
相关论文
共 132 条
[1]  
Bolla M(2002)Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 103-106
[2]  
Collette L(1997)Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 295-300
[3]  
Blank L(2002)Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate-cancer Int J Radiat Oncol Biol Phys 53 581-587
[4]  
Warde P(2001)The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 49 679-684
[5]  
Dubois JB(2000)RTOG protocol 92-02: a phase III trial of the use of long term total androgen supression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 48 112-114
[6]  
Mirimanoff RO(1993)The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer J Urol 150 110-1021
[7]  
Storme G(1997)Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1013-623
[8]  
Bernier J(1995)Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 616-1252
[9]  
Kuten A(2001)Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 1243-1924
[10]  
Sternberg C(2003)Phase III trial of androgen suppression adjuvant to definitive radiotherapy: long term results of RTOG study 85-31 Proc Am Soc Clin Oncol 22 381-1911